Pure Global
NCT06404502

Feasibility and Acceptability of PRISMA for Prisoners in Switzerland

Feasibility and Acceptability of PRISMA for Prisoners in Switzerland - a Pilot Randomised Controlled Trial
University of Zurich·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Psychological Distress,Anxiety,Depression,Suicidal Ideation
Drug/Device/Intervention
PRISMA
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
University of Zurich
Location
Zürich, Switzerland
Timeline & enrollment
Phase
N/A
Start date
Dec 08, 2023
End date
Aug 31, 2024
Enrollment
40 participants
Primary outcome

Verification procedure to the measurement in psychological distress,Verification procedure to the measurement in psychological distress

Summary

In response to the significant mental health challenges faced by pretrial detainees, the
 Swiss Federal Justice Department has initiated a model trial in pretrial detention centres in
 Zurich and Bern. This model trial, named in German as a Modellversuch, is designed to
 enhance detainees' wellbeing and evaluates various interventions through a randomized
 controlled trial. The Prison Stress Management (PRISMA) programme, a key intervention
 derived from the WHO's cognitive-behavioral therapy strategies, seeks to address the lack of
 mental health support within jails.
 
 The goal of this pilot RCT is to evaluate the feasibility and acceptability of PRISMA for
 inmates inform a full-scale, definitive randomized controlled trial.

ICD-10 classifications
Other depressive episodesMood [affective] disordersMental and behavioural disordersOther recurrent depressive disordersSpecific personality disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06404502
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06404502 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Zurich and is currently Recruiting. The study focuses on Psychological Distress,Anxiety,Depression,Suicidal Ideation. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.